Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C

Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Chronic infection with HCV has an estimated prevalence of 1.6-2.0% worldwide and is a major cause of liver-related death. The first attempts to halt the progression of infection relied on the empirical use of interferon (IFN), a naturally occurring cytokine that is implicated in antiviral innate immunity. The first studies of this treatment in the early 1990s, however, led to disappointing response rates. These response rates subsequently improved with the empirical addition of the guanosine analog ribavirin to the treatment regimen. To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s-PEG-IFN-α2a and PEG-IFN-α2b. These two compounds differ markedly in size, structure, site of attachment of the polyethylene glycol moiety and type of bond involved in pegylation, which ultimately confer different pharmacokinetics and biological activity. Unsurprisingly, researchers question whether the two PEG-IFNs also differ in clinical effectiveness, but the re-analysis of restrospective studies and the results of three head-to-head studies have left this issue open. We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-α2a and PEG-IFN-α2b.

Original languageEnglish
Pages (from-to)485-494
Number of pages10
JournalNature Reviews Gastroenterology and Hepatology
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Chronic Hepatitis C
Interferons
Guanosine
Ribavirin
Infection
Innate Immunity
Antiviral Agents
Appointments and Schedules
Pharmacokinetics
Research Personnel
Cytokines
Liver
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Gastroenterology
  • Hepatology

Cite this

Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. / Aghemo, Alessio; Rumi, Maria Grazia; Colombo, Massimo.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 7, No. 9, 09.2010, p. 485-494.

Research output: Contribution to journalArticle

@article{a65b158a896549e197a8c7b82ab87b71,
title = "Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C",
abstract = "Chronic infection with HCV has an estimated prevalence of 1.6-2.0{\%} worldwide and is a major cause of liver-related death. The first attempts to halt the progression of infection relied on the empirical use of interferon (IFN), a naturally occurring cytokine that is implicated in antiviral innate immunity. The first studies of this treatment in the early 1990s, however, led to disappointing response rates. These response rates subsequently improved with the empirical addition of the guanosine analog ribavirin to the treatment regimen. To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s-PEG-IFN-α2a and PEG-IFN-α2b. These two compounds differ markedly in size, structure, site of attachment of the polyethylene glycol moiety and type of bond involved in pegylation, which ultimately confer different pharmacokinetics and biological activity. Unsurprisingly, researchers question whether the two PEG-IFNs also differ in clinical effectiveness, but the re-analysis of restrospective studies and the results of three head-to-head studies have left this issue open. We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-α2a and PEG-IFN-α2b.",
author = "Alessio Aghemo and Rumi, {Maria Grazia} and Massimo Colombo",
year = "2010",
month = "9",
doi = "10.1038/nrgastro.2010.101",
language = "English",
volume = "7",
pages = "485--494",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C

AU - Aghemo, Alessio

AU - Rumi, Maria Grazia

AU - Colombo, Massimo

PY - 2010/9

Y1 - 2010/9

N2 - Chronic infection with HCV has an estimated prevalence of 1.6-2.0% worldwide and is a major cause of liver-related death. The first attempts to halt the progression of infection relied on the empirical use of interferon (IFN), a naturally occurring cytokine that is implicated in antiviral innate immunity. The first studies of this treatment in the early 1990s, however, led to disappointing response rates. These response rates subsequently improved with the empirical addition of the guanosine analog ribavirin to the treatment regimen. To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s-PEG-IFN-α2a and PEG-IFN-α2b. These two compounds differ markedly in size, structure, site of attachment of the polyethylene glycol moiety and type of bond involved in pegylation, which ultimately confer different pharmacokinetics and biological activity. Unsurprisingly, researchers question whether the two PEG-IFNs also differ in clinical effectiveness, but the re-analysis of restrospective studies and the results of three head-to-head studies have left this issue open. We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-α2a and PEG-IFN-α2b.

AB - Chronic infection with HCV has an estimated prevalence of 1.6-2.0% worldwide and is a major cause of liver-related death. The first attempts to halt the progression of infection relied on the empirical use of interferon (IFN), a naturally occurring cytokine that is implicated in antiviral innate immunity. The first studies of this treatment in the early 1990s, however, led to disappointing response rates. These response rates subsequently improved with the empirical addition of the guanosine analog ribavirin to the treatment regimen. To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s-PEG-IFN-α2a and PEG-IFN-α2b. These two compounds differ markedly in size, structure, site of attachment of the polyethylene glycol moiety and type of bond involved in pegylation, which ultimately confer different pharmacokinetics and biological activity. Unsurprisingly, researchers question whether the two PEG-IFNs also differ in clinical effectiveness, but the re-analysis of restrospective studies and the results of three head-to-head studies have left this issue open. We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-α2a and PEG-IFN-α2b.

UR - http://www.scopus.com/inward/record.url?scp=77956395193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956395193&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2010.101

DO - 10.1038/nrgastro.2010.101

M3 - Article

C2 - 20644567

AN - SCOPUS:77956395193

VL - 7

SP - 485

EP - 494

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 9

ER -